Danimer Scientific Inc

Danimer Scientific — Q1 2024 Earnings Presentation

12 slides from Danimer Scientific's earnings presentation, May 7, 2024

  1. Slide 1: First Quarter 2024 Earnings Presentation

    First Quarter 2024 Earnings Presentation May 7, 2024

  2. Slide 2: Disclaimer and Forward-Looking Statements

    This presentation (“Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale w

  3. Slide 3: Fast Facts

    FAST FACTS Founded in 2004 (went public in 2020) 480 patents & pending patent applications 15 partnerships with major brands and distributors 238 Teammates 2018 and 2020 recipient of PLASTICS Innovation in Bioplastics Award Locations in Georgia, Kentucky and New York Manufacturer and developer of PH

  4. Slide 4: Sales Cycle

    Lead Evaluation Pre-Commercial Launch Material Selection Trials R&D / Product Development Certification Work Market Testing Regulatory Initial Sample New leads are screened by sales first, then a joint committee with R&D & sales if necessary; many do not make it past this stage 1 – 5 Years 6 Months

  5. Slide 5: Sales Cycle (continued): Material Selection

    Material Selection ~ 89 customers currently in “Material Selection” zone. Material selection zone is an iterative process, not necessarily a linear process. Sales Cycle (continued) Material Selection Trials R&D / Product Development Certification Work Market Testing Regulatory Initial Sample 5

  6. Slide 6: Warrant Dividend to Deleverage Balance Sheet and Reset Capital Structure

    Provides unique opportunity to deleverage our balance sheet and reset our capital structure. 1 for 3 Pro-Rata Dividend – Record Date May 13, 2024 1 warrant for each 3 shares outstanding Expect approximately 46.7 million warrants would be issued to eligible participants $5.00 Exercise Price – Cash or

  7. Slide 7: Q1 2024 Financial Summary

    Q1 2024 Financial Summary Q1’24 sales overall decreased compared to Q1’23 driven by higher PHA sales of $3.2M, which did not fully offset lower PLA sales of ($4.3M) where were lower due to the impact of the Ukraine conflict. Increased adjusted gross loss primarily impacted by lower sales as compared

  8. Slide 8: Fiscal 2024 Guidance Summary

    Adjusted EBITDA guidance towards the lower end of previously announced range of $(22) million to $(32) million. Capital expenditures guidance range of $8 million to $10 million. Year-end liquidity, which comprises our unrestricted cash and projected availability under the revolver will be in the ran

  9. Slide 9: tess, ~ e

    AN y . tess, ~ e Zé danimer \ oe soienutic. ‘y __ ABiotechnology Company

  10. Slide 10: Adjusted EBITDA Reconciliation

    Adjusted EBITDA Reconciliation 10

  11. Slide 11: Adjusted Gross Profit Reconciliation

    Adjusted Gross Profit Reconciliation 11

  12. Slide 12: Thank You

    a danimer ~ scientific THANK YOU

Danimer Scientific — Q1 2024 Earnings Presentation on 6ix